戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ng solid cancers utilizing viral vectors and adoptive cell transfer.
2 ty while retaining a favorable phenotype for adoptive cell transfer.
3 to T cells, and ex vivo clonal expansion for adoptive cell transfer.
4 TME-localized inhibitory molecules following adoptive cell transfer.
5  and regress multiple solid tumors following adoptive cell transfer.
6 ine delivery or optimal T cell expansion for adoptive cell transfer.
7 tive target for TCR-based gene therapy using adoptive cell transfer.
8 r tumor rejection or inhibit treatment after adoptive cell transfer.
9 e of circulating antitumor T cells following adoptive cell transfer.
10 N-gamma-/- mice, were used as recipients for adoptive cell transfer.
11 tive vaccines and strategies for therapeutic adoptive cell transfer.
12 lymphocytes from melanoma patients following adoptive cell transfer.
13 pulations were rejected within 18 days after adoptive cell transfer.
14 ns and reducing the therapeutic potential of adoptive cell transfers.
15 such as administration of the cytokine IL-2, adoptive cell transfer (ACT) and the recent success of b
16          Depletion of immune elements before adoptive cell transfer (ACT) can dramatically improve th
17 , T cell expansion and persistence following adoptive cell transfer (ACT) have correlated with superi
18                             Efforts to apply adoptive cell transfer (ACT) immunotherapy to patients w
19                                              Adoptive cell transfer (ACT) is a powerful experimental
20                                              Adoptive cell transfer (ACT) is a promising approach to
21                                              Adoptive cell transfer (ACT) is a therapeutic strategy t
22                                              Adoptive cell transfer (ACT) is considered a promising m
23                                 The field of adoptive cell transfer (ACT) is currently comprised of c
24 umor microenvironment (TME), the efficacy of adoptive cell transfer (ACT) is much curtailed in treati
25                                              Adoptive cell transfer (ACT) of engineered T cell recept
26 the potential for immunotherapy based on the adoptive cell transfer (ACT) of engineered T lymphocytes
27                                              Adoptive cell transfer (ACT) of ex vivo-activated autolo
28                                              Adoptive cell transfer (ACT) of purified naive, stem cel
29          A key issue in advancing the use of adoptive cell transfer (ACT) of T cell receptor (TCR) en
30 immunotherapies, including cancer.IMPORTANCE Adoptive cell transfer (ACT) of T cells engineered with
31              Immunotherapy, particularly the adoptive cell transfer (ACT) of tumor-infiltrating lymph
32                                              Adoptive cell transfer (ACT) of tumor-reactive lymphocyt
33                                    Recently, adoptive cell transfer (ACT) of tumor-reactive T lymphoc
34 2 (IL-2) is a component of most protocols of adoptive cell transfer (ACT) therapy for cancer, but is
35                                              Adoptive cell transfer (ACT) with neoantigen-reactive T
36                                              Adoptive cell transfer (ACT), a promising immunotherapeu
37 dy that describes a potential new target for adoptive cell transfer (ACT), in this case CD44 splice v
38 esponse is enhanced through a combination of adoptive cell transfer (ACT), specific vaccination and c
39                                              Adoptive cell transfer (ACT)-based immunotherapies can m
40                                  Response to adoptive cell transfer (ACT)-based immunotherapy in mela
41 sentially as an adjuvant immunotherapy, with adoptive cell transfer (ACT).
42                              More generally, adoptive cell transfer and adoptive immunotherapy may ha
43 f successful cancer immunotherapies, such as adoptive cell transfer and antibody-based immunotherapeu
44                                              Adoptive cell transfer and cell depletion studies reveal
45  its functional loss reduces the efficacy of adoptive cell transfer and checkpoint blockade immunothe
46                                   Before the adoptive cell transfer and DC vaccination, the tumor-bea
47 r, did not require total body irradiation or adoptive cell transfer and resulted in induction of anti
48 ls, with potential clinical implications for adoptive cell transfer and vaccine-based immunotherapies
49                                              Adoptive cell transfer and vascularized segmental pancre
50 ncer vaccines, immune checkpoint inhibitors, adoptive cell transfer, and bispecific antibody therapy.
51 ts for successful tumor rejection through an adoptive cell transfer approach reveals that the presenc
52                     Furthermore, by using an adoptive cell transfer approach, reconstitution of B cel
53 ere dissected using bone marrow chimeras and adoptive cell transfer approaches to profile clonal expa
54 dity, which limits their clinical utility in adoptive cell transfer approaches.
55 eric antigen receptor (CAR) for T-cell-based adoptive cell transfer are among these developments that
56                     Immunotherapies based on adoptive cell transfer are highly effective in the treat
57  chronically-stimulated T cells expanded for adoptive cell transfer are susceptible to cell death in
58 erged as an important component of effective adoptive cell transfer-based immunotherapy for cancer.
59                                Additionally, adoptive cell transfer-based immunotherapy using aging T
60                                              Adoptive cell transfer can mediate durable complete regr
61 upport suggests that IL-12 could be added to adoptive cell transfer clinical strategies in cancer pat
62 aded with the calcium nanoparticles prior to adoptive cell transfer control tumor growth better, resu
63                     Lymphodepletion augments adoptive cell transfer during antitumor immunotherapy, p
64                        In vivo depletion and adoptive cell transfer experiments demonstrated that bot
65                                              Adoptive cell transfer experiments demonstrated that Sph
66                                              Adoptive cell transfer experiments establish an intrinsi
67                                              Adoptive cell transfer experiments revealed that CD44(hi
68  Furthermore, use of gene-deficient mice and adoptive cell transfer experiments revealed that ILC2s w
69 ent tumor models suppressed CTL responses in adoptive cell transfer experiments unless GM-CSF was pro
70  tumor-sensitized T cells is demonstrated by adoptive cell transfer experiments using purified spleen
71          In studies of bone-marrow chimeras, adoptive cell transfer experiments, and analyses of Nemo
72  in both mixed bone marrow-chimeric mice and adoptive cell transfer experiments.
73  protection using anti-CD8 mAb depletion and adoptive cell transfer experiments.
74 tyrosinase-specific TCR could be of value in adoptive cell transfer for melanoma.
75 the main challenge to the development of TIL adoptive cell transfer for metastatic GI cancers may not
76 immune-checkpoint blockade, vaccination, and adoptive cell transfer have been extensively studied in
77 apies such as immune checkpoint blockade and adoptive cell transfer have revolutionized cancer treatm
78 -1/PD-L1 and CTLA-4 checkpoints blockade and adoptive cell transfer) have remarkably improved the res
79 ivated CD8 T cell function in the context of adoptive cell transfer, however, has not been explored i
80 ith porcine skin grafts and administered, by adoptive cell transfer, human cells stimulated in vitro
81                            In the setting of adoptive cell transfer, IL-15-transduced lymphocytes may
82 corporating tumor-reactive CD4(+) T cells in adoptive cell transfer immunotherapies against ovarian c
83 ion of the lung and improves the efficacy of adoptive cell transfer immunotherapy.
84  T cells potentiated the in vivo efficacy of adoptive cell transfer in the B16 tumor model.
85  engineer a wide range of cell types used in adoptive cell transfers, including erythrocytes, macroph
86                Conditional knockout mice and adoptive cell transfer indicate a macrophage and regulat
87 ilic airways inflammation upon intratracheal adoptive cell transfer into congenic mice.
88  cell compartment in immunodeficient mice by adoptive cell transfer leads to a wasting syndrome and i
89 for administering high levels of IL-2 during adoptive cell transfer-mediated antitumor responses.
90                                          The adoptive cell transfer model described in this paper can
91                         We have developed an adoptive cell transfer model in mice to study the abilit
92 re analyzed using cytokine reporter mice, an adoptive cell transfer model, and gene knockout mice.
93 ll trafficking to the liver and spleen in an adoptive cell transfer model.
94 the tolerized mice for testing in active and adoptive cell-transfer models of CS.
95 and evaluated in subcutaneous xenografts and adoptive cell transfer mouse models.
96  six patients were enrolled on a protocol of adoptive cell transfer of enriched neoantigen-specific T
97                                              Adoptive cell transfer of ex vivo-generated immune-promo
98                                              Adoptive cell transfer of macrophages with immunosuppres
99                                This includes adoptive cell transfer of T cells expressing endogenous
100 us immunotherapies under development such as adoptive cell transfer of TCR-engineered CD8(+) T cells,
101                        It is unknown whether adoptive cell transfer of tumor-infiltrating lymphocytes
102                                              Adoptive cell transfer of tumor-infiltrating lymphocytes
103                                              Adoptive cell transfer of wild-type macrophages ameliora
104 re implanted into Rag-/- animals followed by adoptive cell transfer of WT or CD8DeltaALK5 OT-I T cell
105  clonotypes that persisted in vivo following adoptive cell transfer possessed telomeres that were lon
106                         We have developed an adoptive cell transfer protocol to further characterize
107 -engineered T cells are a novel approach for adoptive cell transfer, providing flexible platform for
108                    In this study, we used an adoptive cell-transfer strategy to define the protective
109                                        Using adoptive cell transfer studies in mouse models of allerg
110                                              Adoptive cell transfer studies showed that RAG2(-/-) rec
111                                        After adoptive cell transfer, the CD40L(+) CAR T cells display
112                                              Adoptive cell transfer, the infusion of large numbers of
113                                         Upon adoptive cell transfer, the T cells isolated from the me
114 ced polarization and anti-tumor functions in adoptive cell transfer therapies.
115 e significant progress in the development of adoptive cell-transfer therapies (ACTs) using gene-engin
116                                              Adoptive cell transfer therapy has emerged as a powerful
117 sary for antitumor activity of Th17 cells in adoptive cell transfer therapy models.
118       Combined treatment of vemurafenib plus adoptive cell transfer therapy with lymphocytes genetica
119 hways (i.e. PD-1, CTLA-4, and IDO); and (iv) adoptive cell transfer therapy with T cells engineered t
120 e yielded only limited clinical success, but adoptive cell transfer therapy, particularly following a
121 hough IL-9 has potent anti-tumor activity in adoptive cell transfer therapy, some models suggest that
122  with chemo-immunotherapy, nanomedicine, and adoptive cell transfer therapy, we aim to lay the ground
123  to enhance the effect of cancer vaccines or adoptive cell transfer therapy.
124 ies such as immune checkpoint inhibitors and adoptive cell transfer, TILT-123 (Ad5/3-E2F-D24-hTNFalph
125 s including laser-Doppler perfusion imaging, adoptive cell transfer to ischemic muscle, immunoblot an
126 major implications for the design of current adoptive-cell transfer trials.
127 ession of CTLs that is often observed during adoptive cell transfer tumor immunotherapy and identify
128                                              Adoptive cell transfer utilizing tumour-targeting cytoto
129 s study, using conditional knockout mice and adoptive cell transfer, we found that moDCs are essentia
130 mice missing different leukocyte subsets and adoptive cell transfers, we demonstrated the involvement
131                                     Finally, adoptive cell transfers were implemented to characterize
132                                     Finally, adoptive cell transfers were performed to characterize t
133  with agents that augment host immunity, and adoptive cell transfer will be discussed.

 
Page Top